| 0.5626 0.107 (23.38%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.85 | 1-year : | 1.06 |
| Resists | First : | 0.73 | Second : | 0.9 |
| Pivot price | 0.56  |
|||
| Supports | First : | 0.45 | Second : | 0.37 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.59 |
| MA(100) : | 0.71 |
MA(250) : | 3.39 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.7 |
D(3) : | 9.8 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 12.53 | Low : | 0.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ OSRH ] has closed below upper band by 34.1%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.76 | 0.76 - 0.76 |
| Low: | 0.52 - 0.52 | 0.52 - 0.52 |
| Close: | 0.6 - 0.6 | 0.6 - 0.61 |
OSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.
Fri, 21 Nov 2025
OSR Holdings, Inc. (OSRH) Stock: Jumps 27% Amid Vaximm AG's Strategic Licensing Agreement - CoinCentral
Fri, 21 Nov 2025
OSR Holdings (NASDAQ: OSRH) Stock: CEO Appointment Sparks 24.42% Jump in Stock Price - parameter.io
Fri, 21 Nov 2025
OSR Holdings stock soars after Vaximm enters licensing term sheet - Investing.com
Fri, 07 Nov 2025
OSR Holdings Inc expected to post a loss of 12 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 46.7 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 758 (K) |
| Shares Short P.Month | 528 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.46 |
| Profit Margin | 0 % |
| Operating Margin | -605.9 % |
| Return on Assets (ttm) | -1.9 % |
| Return on Equity (ttm) | -9.3 % |
| Qtrly Rev. Growth | -23.8 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | -0.01 |
| EBITDA (p.s.) | 0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | -1.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.17 |
| Price to Sales | -143.71 |
| Price to Cash Flow | -3.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|